Mutations of the epidermal growth factor receptor in non-small cell lung cancer – Search and destroy

摘要: The targeting of the ATP binding pocket epidermal growth factor receptor (EGFR) tyrosine kinase, by small molecule drugs gefitinib and erlotinib, represents a promising new therapeutic strategy in non-small cell lung cancer. However, it is now apparent that only subset patients responds to such treatment. Two publications early 2004 reported presence activating mutations EGFR kinase gene conferring exquisite sensitivity these drugs. Several have since prospective data consistent with this finding. This brief review summarises mutation from 15 studies terms frequency clinicopathological features correlation response inhibition. A paradigm for routine detection needed facilitate patient selection treatment further studies.